Sign in

Private company

AGILE THERAPEUTICS INC

In its 2024 annual report the company says: “We are a women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. We are committed to innovating in women’s healthcare where there continues to be unmet needs – not only in contraception – but also in other meaningful women’s health therapeutic areas. We are focused on our advancement as a commercial company and the growth of our first and only product, Twirla, a once-weekly prescriptions combination hormonal contraceptive patch.”4 It is headquartered in Princeton, United States.2

Last updated Oct 21, 2026.

Overview

  • IndustryPharmaceutical Preparations2
  • HeadquartersPrinceton, United States2
  • Incorporated inDE3
  • Business address500 College Road East, Suite 310, Princeton, Nj 08540-66353
  • Filer categoryNon-accelerated filer, Smaller reporting company3
  • Legal formCorporation2
  • LEI529900AJZBQ4SDDB0T372
  • StatusActive2
  • LEI statusLapsed (not renewed)2
  • Registered addressc/o Capitol Corporate Services, Inc., 1111B S Governors Avenue, 19904 Dover, United States2
  • Registered withDivision of Corporations, Department of State, 28293242

See how the biggest companies compare on our leaderboards

We are a women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. We are committed to innovating in women’s healthcare where there continues to be unmet needs – not only in contraception – but also in other meaningful women’s health therapeutic areas. We are focused on our advancement as a commercial company and the growth of our first and only product, Twirla, a once-weekly prescriptions combination hormonal contraceptive patch.4 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2023

54.2%Gross margin5
-101.5%Operating margin5
-73.8%Net margin5
80.0%Revenue growth, 20235

Where the money goes

Where each dollar of revenue went, fiscal 2023

  • Cost of revenue46¢$9.0M
  • Research and development11¢$2.2M
  • Other costs36¢$7.0M
  • Interest7¢$1.4M

Out of $19.6M in revenue.5 The company lost money this year.

Financial statements

Revenue67895$19.6M in 2023
0$5.0M$10.0M$15.0M$20.0M2017: $0$020172018: $0$020182019: $0$020192020: $749.0K$749.0K20202021: $4.1M$4.1M2021+448%2022: $10.9M$10.9M2022+165%2023: $19.6M$19.6M2023+80%
Gross profit95$10.6M in 2023+2173% since 2020
-$10.0M-$5.0M0$5.0M$10.0M$15.0M2020: $467.0K$467.0K20202021: -$6.6M-$6.6M20212022: $4.0M$4.0M20222023: $10.6M$10.6M2023+162%
Operating income8101195-$19.9M in 2023−26% since 2017
-$80.0M-$60.0M-$40.0M-$20.0M02017: -$26.8M-$26.8M20172018: -$19.5M-$19.5M2018−27%2019: -$18.9M-$18.9M2019−3%2020: -$49.1M-$49.1M2020+160%2021: -$71.0M-$71.0M2021+45%2022: -$52.6M-$52.6M2022−26%2023: -$19.9M-$19.9M2023−62%
Net income8101195-$14.5M in 2023−49% since 2017
-$80.0M-$60.0M-$40.0M-$20.0M02017: -$28.3M-$28.3M20172018: -$19.8M-$19.8M2018−30%2019: -$18.6M-$18.6M2019−6%2020: -$51.9M-$51.9M2020+179%2021: -$71.1M-$71.1M2021+37%2022: -$25.4M-$25.4M2022−64%2023: -$14.5M-$14.5M2023−43%
Fiscal year2017201820192020202120222023
Revenue$06$07$08$749.0K9$4.1M5$10.9M5$19.6M5
Cost of revenue$282.0K9$10.7M5$6.8M5$9.0M5
Gross profit$467.0K9-$6.6M5$4.0M5$10.6M5
Research and development$14.4M8$9.8M10$9.9M11$13.5M9$6.2M5$3.3M5$2.2M5
Operating expenses$64.4M5$56.6M5$30.5M5
Operating income-$26.8M8-$19.5M10-$18.9M11-$49.1M9-$71.0M5-$52.6M5-$19.9M5
Interest$1.9M8$1.1M10$3.1M9$3.9M5$3.1M5$1.4M5
Income before tax-$71.1M5-$30.1M5-$14.5M5
Income tax-$477.0K10-$4.7M5
Net income-$28.3M8-$19.8M10-$18.6M11-$51.9M9-$71.1M5-$25.4M5-$14.5M5
Earnings per share-$0.3811-$24.409-$1,464.205-$58.795-$6.715
Earnings per share (diluted)-$0.3811-$24.409-$1,464.205-$58.795-$6.715
Shares (weighted, basic)48.5K shares5432.2K shares52.2M shares5
Shares (weighted, diluted)48.5K shares5432.2K shares52.2M shares5

Compare AGILE THERAPEUTICS INC with another company

Corporate structure

AGILE THERAPEUTICS INC sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of AGILE THERAPEUTICS INC

  • Beryl Capital Management LLC Filed SC 13G/A on AGILE THERAPEUTICS INC, latest Nov 13, 2024 (2 filings since Jul 9, 2024)
  • Doug Mastrangeli Filed SCHEDULE 13G on AGILE THERAPEUTICS INC, latest Aug 26, 2024
  • TANG CAPITAL PARTNERS LP Filed SC 13G on AGILE THERAPEUTICS INC, latest Jul 22, 2024
  • Roger M. Klein Filed SC 13G on AGILE THERAPEUTICS INC, latest Jul 2, 2024
  • Lind Global Fund II LP Filed SC 13G/A on AGILE THERAPEUTICS INC, latest Feb 13, 2024 (3 filings since Jul 12, 2022)
  • INTRACOASTAL CAPITAL, LLC Filed SC 13G/A on AGILE THERAPEUTICS INC, latest Feb 6, 2024 (3 filings since Jul 11, 2022)
  • PERCEPTIVE ADVISORS LLC Filed SC 13G/A on AGILE THERAPEUTICS INC, latest Feb 14, 2023 (2 filings since Feb 14, 2022)
  • VANGUARD GROUP INC Filed SC 13G/A on AGILE THERAPEUTICS INC, latest Feb 9, 2022
  • AGILE THERAPEUTICS INC Princeton, New Jersey, United States

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What AGILE THERAPEUTICS INC reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$253.0K5 Dec 31, 2023$253.0K5 Dec 31, 20220%
Accumulated depreciation$178.0K5 Dec 31, 2023$76.0K5 Dec 31, 2022+134.2%
Property and equipment, net$75.0K5 Dec 31, 2023$177.0K5 Dec 31, 2022−57.6%
Operating-lease assets (leased space)$412.0K5 Dec 31, 2023$695.0K5 Dec 31, 2022−40.7%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$2.6M5 Dec 31, 2023$5.2M5 Dec 31, 2022−51.3%

Inventory

ItemLatestA year beforeChange
Inventory, total$2.7M5 Dec 31, 2023$1.3M5 Dec 31, 2022+105.6%

Leadership

Who has led AGILE THERAPEUTICS INC, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Alfred Altomari2014–2024

Chair

  1. Alfred Altomari2017

Chief financial officer

  1. Scott M. Coiante2014–2024
  2. Dennis Reilly2019–2022
201520202025
Board members and other officers (22)

Timeline

  1. Aug 26, 20248-K Entered a material agreement; Ended a material agreement; Completed an acquisition or sale38
  2. Jul 16, 20248-K Financial statements and exhibits39
  3. Jul 15, 20248-K Financial statements and exhibits40
  4. Jun 26, 20248-K Entered a material agreement; Regulation FD disclosure41
  5. May 21, 20248-K Entered a material agreement42
  6. May 15, 20248-K Results of operations43
  7. Apr 9, 20248-K Results of operations; Regulation FD disclosure44
  8. Mar 28, 20248-K Results of operations45
  9. Mar 25, 20248-K Listing notice or transfer; Other events46
  10. Mar 14, 20248-K Other events47
  11. Feb 23, 20248-K Entered a material agreement; Unregistered sale of shares; Change to shareholders' rights48
  12. Feb 15, 20248-K Entered a material agreement; Results of operations; Other events49
  13. May 22, 2014New chief executive Alfred Altomari becomes CEO14

Calendar

When it reported results

  1. May 15, 2024Reported quarterly or annual results43
  2. Apr 9, 2024Reported quarterly or annual results44
  3. Mar 28, 2024Reported quarterly or annual results45
  4. Feb 15, 2024Reported quarterly or annual results49
  5. Nov 9, 2023Reported quarterly or annual results50
  6. Aug 9, 2023Reported quarterly or annual results51
  7. May 11, 2023Reported quarterly or annual results52
  8. Apr 28, 2023Reported quarterly or annual results53

Drug trials and FDA: recently

  1. Nov 16, 2021Phase 4 trial completed Phase 4 trial of Twirla® (Levonorgestrel/Ethinyl Estradiol) Transdermal System in Residual Drug Amount of EE and LNG, run by Insud Pharma: primary completion Nov 16, 2021, results posted Aug 27, 2026 (ClinicalTrials.gov NCT07739589).54

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). Trials from ClinicalTrials.gov, as the sponsor registered them (expected dates are the sponsor's own and often move); approvals and advisory committee meetings from the FDA. The FDA does not publish its decision (PDUFA) dates. The full markets calendar

Filings

206 filings to the SEC since October 2021: 4 annual reports, 10 quarterly reports, 61 major events, 49 insider forms, 14 large holders, 68 other. The latest 20:

  1. Nov 13, 2024SC 13G/A EDGAR
  2. Sep 30, 202415-12G EDGAR
  3. Aug 28, 2024RW EDGAR
  4. Aug 27, 2024EFFECT EDGAR
  5. Aug 27, 2024EFFECT EDGAR
  6. Aug 27, 2024EFFECT EDGAR
  7. Aug 26, 2024SCHEDULE 13G EDGAR
  8. Aug 26, 20244 OWNERSHIP DOCUMENT EDGAR
  9. Aug 26, 20244 OWNERSHIP DOCUMENT EDGAR
  10. Aug 26, 20244 OWNERSHIP DOCUMENT EDGAR
  11. Aug 26, 20244 OWNERSHIP DOCUMENT EDGAR
  12. Aug 26, 20244 OWNERSHIP DOCUMENT EDGAR
  13. Aug 26, 20244 OWNERSHIP DOCUMENT EDGAR
  14. Aug 26, 20244 OWNERSHIP DOCUMENT EDGAR
  15. Aug 26, 20244 OWNERSHIP DOCUMENT EDGAR
  16. Aug 26, 20244 OWNERSHIP DOCUMENT EDGAR
  17. Aug 26, 20244 OWNERSHIP DOCUMENT EDGAR
  18. Aug 26, 20244 OWNERSHIP DOCUMENT EDGAR
  19. Aug 26, 2024S-8 POS EDGAR
  20. Aug 26, 2024S-8 POS EDGAR

The 206 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

4 open-market trades by officers, directors and large owners since October 2021: 4 buys and 0 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Aug 26, 2022ALTOMARI ALFREDChief Executive OfficerBuy50,000$0.45$22.5KForm 4
Oct 13, 2021Reilly DennisChief Financial OfficerBuy58,824Form 4
Oct 13, 2021ALTOMARI ALFREDChief Executive OfficerBuy58,824Form 4
Oct 13, 2021PERCEPTIVE ADVISORS LLC10% ownerBuy5,734,560$0.85$4.9MForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

SEC filer profile

How AGILE THERAPEUTICS INC is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARAGILE THERAPEUTICS INC1
  • CIK0001261249
  • Filer statusNon-accelerated filer<br>smaller reporting company1
  • Incorporated inDelaware1
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address500 College Road East, Suite 310, Princeton, NJ 08540-66351
  • Phone609-683-18801
  • Shares outstanding6,904,498 as of Aug 12, 202413
  • Public float$4.8M as of Jun 30, 202363
  • On EDGAR sinceAug 25, 20031
  • Filings651 in all: 4 (195), 8-K (182), 10-Q (31), 3 (29), SC 13G/A (29), 424B5 (23), SC 13G (18), CORRESP (13)1
    All 45 form types

    DEF 14A (12), 10-K (10), S-1/A (10), EFFECT (9), D (8), S-8 (8), S-8 POS (8), SC 13D/A (8), UPLOAD (7), S-1 (5), 8-K/A (4), DEFA14A (4), 424B4 (3), POS AM (3), PRE 14A (3), REGDEX (3), S-3 (3), ARS (2), RW (2), SC 13D (2), 10-K/A (1), 10-Q/A (1), 15-12G (1), 25-NSE (1), 3/A (1), 4/A (1), 8-A12B (1), 8-A12G (1), CERTNAS (1), CT ORDER (1), D/A (1), DEFM14A (1), FWP (1), PREM14A (1), REGDEX/A (1), S-1MEF (1), SCHEDULE 13G (1)

  • Latest filingsAnnual report (10-K) Mar 28, 2024
    Quarterly report (10-Q) Aug 12, 2024
    Proxy statement (DEF 14A) Apr 28, 2023
    Latest 8-K (8-K) Aug 26, 2024

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
    SEC EDGAROther events
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59
  60. 60
  61. 61
  62. 62
  63. 63